FRANKFURT Mon Dec 23, 2013 4:26am EST
FRANKFURT Dec 23 (Reuters) - The European Commission has approved the use of Merck KGaA's cancer drug Erbitux to treat patients with RAS wild-type metastatic colorectal cancer, the company said on Monday.
The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, had recommended the approval in late November. (Reporting by Christoph Steitz; editing by Tom Pfeiffer)
FRANKFURT Dec 23 (Reuters) - The European Commission has approved the use of Merck KGaA's cancer drug Erbitux to treat patients with RAS wild-type metastatic colorectal cancer, the company said on Monday.
The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, had recommended the approval in late November. (Reporting by Christoph Steitz; editing by Tom Pfeiffer)
via Smart Health Shop Forum http://feedproxy.google.com/~r/SmartHealthShopForum/~3/qUF0DKqo1i0/16070-eu-backs-mercks-erbitux-broader-colon-cancer-treatment.html
No comments:
Post a Comment